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Staphylococcus aureus is a major human pathogen, responsible for a wide range of diseases. 
Its remarkable ability to develop resistance to antibiotics made S. aureus a worldwide issue in 
clinical medicine. One of the causes of its success as a pathogen is the peculiar array of 
immune evasion factors that enable the bacterium to avoid host defenses. Among these 
factors, the staphylococcal protein A (SpA), is thought to have a crucial role in staphylococcal 
immune evasion thanks to its IgG-binding activities. Indeed, SpA is able to bind the Fc region 
of IgG, hence preventing the recognition of the Fc by the host immune system and allowing 
escape from antibody-mediated neutrophil phagocytosis. Moreover SpA can also bind the 
VH3 domain of B cell receptors acting as a superantigen and thus leading to an impairment of 
the B cell response. With the intent of determining the prevalence of SpA expression in 
staphylococcus isolates, we screened a large panel of strains for SpA expression. 
Interestingly, in about 7% of the isolates, SpA was not detectable by Western blot despite the 
presence of the gene. Of note, the strains lacking SpA expression (SpA
-
 strains) are mainly 
associated with the USA100/CC5 lineages, which are responsible for Hospital Acquired (HA) 
infections. The analysis of the genomes of the SpA
-
 strains revealed that the loss of SpA 
expression may have more than one genetic basis, since only a subset of SpA
-
 isolates carried 
a conserved mutation in the spA 5’UTR sequence. The analysis of transcript levels of more 
than 90 virulence factors showed a unique feature in SpA
- 
strains, in that a higher capsule 
biosynthesis operon (cap operon) mRNA was identified along with lower spA transcripts. The 
negative correlation between spA and cap operon transcripts is shared by strains coming from 
distant geographic origins, thus indicating this as a common adaptation in SpA
-
 strains. The 
analysis of the regulatory network controlling spA and cap operon transcription highlights 
how a number of factors contribute to the balance of these two virulence factors and their 
mutually exclusive expression. The difference in cap operon RNA levels was reflected in the 
amount of capsule produced, which is significantly higher in the SpA
-
 strains. We then 
investigated the ability of anti-capsule antibodies to induce phagocytic uptake by neutrophils, 
which resulted in specific internalization only in the SpA negative background. 
Capsule and SpA are both important immune evasion factors that prevent 
opsonophagocytosis. Given their inversely regulated expression, we hypothesize that while 





of SpA and capsule in immune evasion is of utmost importance in S. aureus isolates. 
Moreover, the expression profile of capsule and SpA among different S. aureus isolates 








3.1 Disease and pathology 
Staphylococcus aureus (Fig.1) is a Gram-positive bacterium that colonizes the human nares 
and skin [1, 2]. Despite the fact that about 30% of the population carries S. aureus 
asymptomatically [2], it is a frequent cause of opportunistic infections that lead to a huge 
variety of diseases, ranging from skin and soft tissue infection to infective endocarditis and 
bacteremia [3]. Of note, S. aureus is one of the leading causes of both hospital and 
community acquired infections [4-6]. The mortality rate of staphylococcal bacteremia in the 
US is approximately 2 to 10 deaths annually per 100,000 population and is higher than 
mortality rates of AIDS, tuberculosis and viral hepatitis, and comparable to that of breast and 
prostate cancer [7]. The elevated incidence of staphylococcal infections in hospital settings 
(above all, staphylococcal bacteremia) has been attributed to several factors, for example the 
breaching of the skin or the mucosa upon surgical intervention allows the pathogen to 
overcome the external body barrier, while its ability to form biofilm S. aureus particularly 
adept at infecting foreign bodies within the human host, such as vascular and urinary 
catheters, prosthetic cardiac valves or prosthetic joint devices [3]. The remarkable versatility 
of S. aureus renders it is also one of the major causes of community (CA) acquired infections, 
where it is able to infect otherwise healthy individuals not associated with any predisposing 
risk factor. CA infections are usually associated with strains with distinct genetic background 
from health care associated (HA) strains, and are characterized by enhanced virulence [8-10]. 
Besides the multiple pathology types and the different settings in which they are involved, 
staphylococcal infections are an increasing concern in human health because of antibiotic 
resistance. During the past decades indeed we witnessed the emergence of S. aureus strains 























3.2 Antibiotic resistance 
Since the introduction of penicillin in the 1940s, S. aureus has shown a remarkable ability to 
gain new antibiotic resistance. The emergence of new antibiotic resistant strains can be seen 
as series of waves (Fig.2), as result of the introduction of newly discovered antimicrobial 
compounds [11]. The first wave started in the mid-1940s, with the emergence of penicillin 
resistant S. aureus strains in USA hospitals. From the hospitals those strains rapidly spread 
causing community acquired infections, and by the end of 1950s they were pandemic. The 
mechanism of resistance was based on a plasmid encoded penicillase that lead to the 
inactivation of the antibiotic. The introduction of methicillin lead to the disappearance of the 
infections due to the most relevant penicillin resistant clone, but already in 1961 the first 
methicillin resistant S. aureus (MRSA) strains were identified. These first MRSA strains were 
limited to European hospitals with sporadic reports in USA, without spreading to the 
community or the rest of the world. The mechanism of this resistance was not associated with 
drug inactivation, but it conferred protection to a broad set of antibiotics: the entire class of β-
lactam including penicillins, cephalosporins, and carbapenems. Later, the mechanism was 
associated with a specific gene mecA which encodes for the low affinity penicillin binding 
protein PBP2a. By the 1980s the infections determined by those archaic MRSA strains waned 
in Europe and from the late 1970s, outbreaks of MRSA strains were reported in the US and 
spread into the hospitals, a pandemic that continues to present times. Given the rising 
emergence of methicillin resistant clones, vancomycin was increasingly used as reliably 
antimicrobial in S. aureus infections. This selective pressure led to the emergence of two 
distinct mechanisms of resistance. In 1996 the first Vancomycin Intermediate Staphylococcus 
aureus strain (VISA) was isolated in Japan [12]. This clone was characterized by a 
vancomycin minimum inhibitory concentration of 4-8 µg ml
-1
 determined by an increased 
thickness of the cell wall able to block antibiotic molecules. The VISA strains are not 
associated to the acquisition of specific antibiotic resistance genes, but the phenotype is 
reached through a step wise process in which several mutations are accumulated in the 
genome, particularly in cell wall metabolism regulatory genes [13]. In 2002, shortly after the 
first VISA report, also vancomycin resistant strains (VRSA) emerged [14]. VRSA strains are 







vancomycin. So far VISA strains are mostly associated with health care settings, while VRSA 
strains are extremely rare. 
Almost in the same period of the emergence of VISA strains, increasing numbers of MRSA 
infections were reported to be community acquired (CA-MRSA) and not associated to 
nosocomial settings. Those strains show distinctive characteristics when compared to HA-
MRSA, like a different pulsed field gel electrophoresis pattern and the susceptibility to most 
antibiotics other than β-lactams, indicating that their evolution occurred in a separate way. 
Moreover, while the HA-MRSA strains were unable to disseminate in the community setting, 
CA-MRSA strains disseminated also in the health care setting. The reasons for this difference 
reside in peculiar virulence ability and diverse pathogenesis, like the greater ability to spread 
by skin to skin contact [11, 15, 16]. The characterization by multilocus sequence type (MLST) 
and Pulsed field gel electrophoresis (PFGE) indicates that nowdays the most common lineage 
of HA MRSA in United states is Clonal complex 5 (ST5) and USA100 PFGE type, while the 
predominant CA MRSA clone belongs to Clonal complex 8 (ST8) and USA300 PFGE type. 
 
 
Figure 2 Emergence of antibiotic resistance in time. The panel shows the timeline of the 
introduction of new antibiotics in medical use, and the following emergence of antibiotic resistant 








3.3 Staphylococcus aureus virulence factors 
The ability to act both as a commensal or a pathogen and the ability to cause different types of 
infection exemplifies the versatile nature of Staphylococcus aureus. One of the reasons for its 
success in its multi-faced physiology reside in its unique array of virulence and immune 
evasion factors that allows the bacterium to invade and escape host defenses (Fig.3). These 
include factors that help the bacterium in the different environments encountered during 
commensal colonization and the different stages of infection, like adhesion factors, factors 
able to block complement cascade, impair neutrophils chemotaxis, inhibit 
opsonophagocytosis and kill immune host cells [18-22]. In the complex scenario of a 
staphylococcal infection, it is not uncommon that the same factor is responsible for more than 
one function, or that the same functions are carried out by several proteins. Although the 
principal role of the various virulence factors may not be the same, it is interesting to note that 
S. aureus employs multiple strategies to accomplish one single task. Considering this 
redundancy it is likely that none of these factors is strictly necessary for virulence. In fact, 
infection-related clinical isolates may naturally be deficient in a range of these factors [23, 
24]. Furthermore, animal model studies comparing virulence of isogenic single mutants show 
attenuated but not completely abolished ability to infect [25-27].  
Figure 3 Schematic representation of major staphylococcal virulence factors. Staphylococcal 
virulence determinants include secreted and surface attached factors, involved in adhesion, immune 






3.3.1 Cell Wall Anchored proteins 
S. aureus can express up to 24 surface proteins covalently bound to the cell wall, known as 
Cell Wall Anchored (CWA) proteins. Those proteins have secretory signals in the N terminus, 
which directs the precursor to the secretory system in the cell membrane, and a characteristic 
sorting signal containing the LPXTG motif in the C terminus, required for the anchorage to 
the cell wall. The CWA family can be divided in several major groups of proteins, based on 
structural and functional similarities [28]. The microbial surface component recognizing 
adhesive matrix molecules (MSCRAMM) is the most represented group of CWA.  
Clumping factor A (ClfA) is the archetype of the MSCRAMM family, and is the major 
staphylococcal fibrinogen-binding protein. The ClfA N-terminus is able to bind the γ-chain 
located in the C-terminus of fibrinogen, which is formed of two specular tripeptide chains 
connected at the N-terminus [29-31]. The same fibrinogen molecule can be bound by two 
ClfA molecules coming from different bacterial cells, which determines cells clumping in 
vitro [31]. In vivo bacterial cells are coated with fibrinogen molecules, which impair opsonin 
deposition and phagocytosis [32]. Furthermore, ClfA can bind to complement factor I, which 
results in the cleavage of C3b to inactive iC3b [33, 34], impairing complement cascade and 
complement-mediated phagocytosis[35]. 
Another fibrinogen binding protein that belongs to the MSCRAMM family is Clumping 
factor B (ClfB) [36]. Differently to ClfA, it binds to α- and β- chains of fibrinogen [37], as 
well as cytokeratin 10 [38]. ClfB was shown to promote adherence to human keratinocyte 
[39], and it has a major role S. aureus nasal carriage [40, 41]. The different role of ClfA and 
ClfB is underlined by their reported different expression profile in in vitro growth: where clfB 
is mainly transcribed in the exponential phase of growth, clfA is upregulated during stationary 
phase [42]. 
A class of CWA proteins is characterized by the presence of the Near iron transporter (NEAT) 
motif, which can bind hemoglobin or haem [28]. The Iron surface determinants (Isd) A,B,H 
proteins can harbor from one to three NEAT motifs, and are involved in iron acquisition 
within the host, were it is limited [43]. Haem is bound on the cellular surface and then 
transported in to the cytoplasm, where iron is extracted. The CWA Isd proteins have several 





colonization [44], IsdB was shown to contribute to adherence and internalization by non-
phagocytic human cells [45], while IsdH enhances the inactivation of C3b [46]. 
3.3.1.1 Staphylococcal protein A 
Staphylococcal protein A (SpA) is one of the major virulence factors of Staphylococcus 
aureus. SpA is a 45-60 k Da protein that can be cell wall associated or secreted [47, 48]. It is 
composed by three regions: the IgG binding domain in the N terminus, the X variable region 
and the peptidoglycan tail in the C terminus (Fig.4) [48-50]. The IgG binding region is 
composed normally by five homologous domains (called EABCD), each one folds into triple 
α helical bundles each responsible for two main binding activities, such as the Fcγ portion of 
human IgM, IgD and class I, II and IV IgGs[51-53], the VH3 portion of human B cell receptor 
[52, 54, 55], tumor necrosis factor 1[56], epithelial growth factor receptor [57] and Von 
Willebrand Factor [58, 59]. The X region divides the IgG binding domains from the cell 
surface and it is composed by an Xr variable region and the constant region Xc. The Xr region 
is formed by highly variable numbers of octapeptide repeats, and its sequencing can be used 
as typing method for staphylococcal strains [60]. The constant Xc region contains the LPXGT 
motif sorting signal, that is needed for cell-wall anchoring [61]. When the protein is released 
from cell surface it presents an attached peptidoglycan tail of variable length, which has been 
shown to be relevant in the immunological functions of the protein [62]. 
Figure 4 Schematic representation of staphylococcal protein A. In white, at the N-terminus the 
signal sequence, followed by five IgG binding domains, then the repetitive Xr region and the X 











SpA plays a central role in the multilayered phenomenon which is staphylococcal immune 
evasion, exerting several functions. The Fc binding activity allows SpA to sequester the 
antibodies and to display them with the wrong orientation, determining a reduced antibody 
dependent phagocytosis [63, 64]. The combination of Fc binding activity and the Fab binding 
of VH3, is thought to determine immune complexes that affect Neutrophil recruitment and 
complement activation [65]. 
Through VH3 Fab binding SpA can act also as a B cell superantigen[66], activating B cells in 
a non-specific manner [67]. The results of this B cell activation are not clear yet. Initial 
studies suggested a role in B cell apoptosis [68], while further studies showed that SpA leads 
to B cell expansion and antibody expression [62]. 
The inhibition of opsonophagocytosis and the superantigen activity of SpA are thought to be 
the main reasons for the poor efficacy of adaptive immune response against Staphylococcus 






















3.3.2 Other surface exposed factors 
3.3.2.1 Second IgG binding protein 
A second immunoglobulin-binding protein (Sbi) is a cell envelope-associated factor that can 
be secreted [69]. Its N-terminus portion contains two IgG binding domains that share 
similarity to SpA IgG binding domains, followed by two domains that bind the C3 
complement component. The C-terminus part is composed of a proline-rich domain and a 
tyrosine threonine-rich domain that is involved in the attachment of the protein to the cell 
envelope. The C3 binding domain is also able to bind the factor H complement component, 
forming a tripartite complex with factor H and C3, leading to the consumption of C3 [70].The 
two binding domains confer to the protein multiple immune evasion properties, which have 
different relevance if the protein is secreted or attached to the cell membrane. In fact the IgG 
binding activity protects the bacteria when the protein is exposed on the cell surface, while the 
C3 binding domain preserves the pathogen when the protein is released [69]. Considering 
these peculiar properties, it is clear how Sbi is a unique immune evasion factor that 
specifically targets both innate and acquired immunity. 
3.3.2.2 Capsule 
Most staphylococcal clinical isolates express a thin layer of capsule, often referred to as 
microcapsule, composed of different serotypes. The serotype 5 and the serotype 8 account for 
more than the 70% of clinical isolates[71]. The cap operon is composed of 16 genes (capA-
capP) which encode for the enzymes needed for capsule synthesis [72]. A cluster of four 
genes (capH-capK) gives serotype 5 or 8 specificity, while the rest of the operon shares more 
than the 97% of aminoacidic identity among the two serotypes [72]. The contribution of 
capsular polysaccharide in S. aureus virulence has been debated [73], and its relevance seems 
to depend on the specific strain and growth conditions [27]. In fact several external stimuli 
influence capsule expression, which for instance changes drastically if the strain is grown on 
plates or in liquid [27]. More recent works showed that the expression of either capsule 5 or 8 
serotype enhances bacterial protection from opsonophagocytosis in vitro and increased 






3.3.3 Secreted factors 
Among the virulence and immune evasion factors of S. aureus there is a great number of 
secreted molecules that exerts several functions. Staphylokinase (SAK) is a plasminogen 
activator that binds to host plasminogen, and mediates the cleavage of surface bound C3b and 
antibodies [75]. Chemotaxis inhibitory protein of S. aureus (CHIPS) is able to inhibit C5a- 
and fMLP-induced response in neutrophils and macrophages, impairing their recruitment to 
the infection site [76]. CHIPS have several homologs in S. aureus, called FPR-like 1 
inhibitory proteins (FLIPr and FLIPr-like), which act inhibiting the first chemoattractants 
from migrating to the site of infection [77]. 
Killing of immune cells is a key feature in staphylococcal pathogenesis, especially relevant in 
abscess formation. This is achieved through the secretion of a large number of toxins, able to 
damage host cell membrane and eventually lysis. There are three classes of molecules able to 
damage host cell membrane: the pore-forming toxins, β-hemolysin and phenol soluble 
modulins (PSM). The pore-forming toxins are the largest family of such toxins including the 
α-hemolysin, the bi-component leukocidins γ-hemolysin, the Panton Valentine leucocidin 
(PVL), LukED and LukGH/AB. The α-hemolysin is secreted as a monomer, which assembles 
into a homo-heptamer on target cell surface that determines pore formation and cell lysis. 
In the other pore-forming toxins the formation of the pore is mediated by two different 
subunits named F (fast) and S (slow) based on their electrophoresis mobility. All the bi-
component leukocidins share sequence homology, and their mechanism of action is thought to 
be similar. The two components assemble sequentially on the cell surface creating a hetero-
octamer, in which the S and F subunits are alternatively disposed. 
In contrast to pore forming toxins, the β-hemolysin is a neutral sphingomyelinase hydrolysing 
sphingomyelin, which is a plasma membrane lipid and is thought to destabilize membrane 
structure.  
The PSM are small amphipathic peptides, divided in two sub classes based on their length: 
PSMα that includes γ-hemolysin, PSMα1-4 and PSM mec that have a length of 20-26 








3.4 Regulation of S. aureus gene expression 
The huge array of virulence factors and immune evasion systems harbored by S. aureus is not 
always expressed in an indiscriminate way. In fact, S. aureus colonization and infection are 
complex processes that need the activation of specific functions in a coordinate manner in 
response to determined task. The same happens in in vitro growth curves were each virulence 
factor has a peculiar expression profile, which reflects a specific temporal expression during 
the different phases of infection [78]. As a general rule, factors involved in colonization (Cell 
Wall Associated proteins with adhesive and tissue binding functions) are preferentially 
expressed during the exponential phase of an in vitro growth curve, while proteins involved in 
dissemination and spreading of the infection (exoproteins, proteases, toxins, haemolysins) are 
more likely to be expressed in the stationary phase [78]. This expression profile is the result 
of a highly complex and interconnected regulation that enables the pathogen to respond to 
external stimuli and environmental changes [79, 80]. In Staphylococcus aureus two major 
families of global regulators have been identified: (1) the two component signal transduction 
systems (TCS) and (2) the SarA homologs, a global regulator of virulence factors. The TCS 
family normally consists of a membrane bound sensor histidine kinase (HK) and a cytosolic 
response regulator that induces transcriptional responses [79]. The phosphorylation of the 
response regulator mediated by the histidine kinases determines conformational changes that 
modifies the affinity of the DNA binding domain for its target sequence [81]. This simple and 
general scheme of the TCS can vary in different systems, including other accessory proteins 
or cytosolic sensor histidine kinases. S. aureus genome encodes for 16 TCS, involved in 
sensing a variety of external stimuli and affecting diverse cellular processes, ranging from 
quorum sensing and virulence regulation (agr, SaeRS), response to antimicrobials and cell 
wall damage (VraSR, GraXSR, BraRS), cell wall metabolism (WalRK), autolysis (ArlRS, 
LytSR) and cellular metabolism (SrrAB, NreCBA, AirRS, HssSR, KdpDE, PhoRP). SarA 
homologs are composed of single proteins with multiple specific targets across the genome. 
The S. aureus genome shows the presence of eleven SarA homologs (SarA, SarR, SarS, SarT, 
SarU, Rot, SarX, MgrA, SarZ, SarV, SarY) [82]. Those regulators control highly 
interconnected regulons, in which the expression of a target gene is the result of several 
diverse regulations. Moreover, SarA homologs and TCS can influence each other expression, 





S. aureus circulating strains can harbor different alleles of these regulators, as well as 
mutations within the regulatory network, resulting in diverse expression patterns. This can 
influence several aspects of staphylococcal physiology, ranging from antibiotic resistance 
(VISA phenotype), to persistence and adaptation in human host like the Small Colony Variant 
phenotype (SCV) reference. 
These observations point out further the importance that gene regulation has in staphylococcal 
pathogenesis, and its role during infections. 
 
3.4.1 Accessory gene regulator  
The accessory gene regulator system (agr) is the major quorum sensing system of S. aureus as 
well as a major global regulator controlling the expression of a wide number of virulence 
factors. The agr system controls the expression of more than 100 genes, determining the 
transition from a colonizing to an invasive phenotype in a cell density dependent manner. As 
general rule, it promotes transcription of secreted virulence factors (i.e. lipases, protease, 
PSM, haemolysins, leukocidins) and inhibits the expression of cell surface proteins involved 
in adhesion and aggregation (SpA, FnbA, FnbB). The agr locus encodes for two divergent 
transcripts, the RNAII and RNAIII, controlled by the promoters P2 and P3, respectively. The 
RNAII contains the coding sequences of the quorum sensing system agrBDCA. agrB encodes 
for a transmembrane peptidase that is involved in processing and secreting the AgrD 
propeptide into the active pheromone called autoinducing peptide (AIP). AgrC is the sensor 
kinase that undergoes transient phosphorylation after binding AIP through the extracellular 
sensor domain. The activation of the sensor kinase AgrC occurs only when the accumulation 
of AIP exceeds a concentration threshold. AgrC then transfers the phosphate group to the 
response regulator AgrA triggering its activity. Phosphorylated AgrA binds to the P2 
promoter inducing RNAII transcription and completing the autoinducing cycle of the quorum 
sensing system. AgrA binds also to the P3 promoter, activating the transcription of RNAIII, 
which is the main effector molecule of the quorum sensing system and functions as a non-
coding RNA as well as a coding RNA encoding the hld gene. AgrA binds to P3 with lower 
affinity compared to P2, indicating that the argBDCA autoinduction occurs before RNAIII 
transcription activation. RNA III modulates the expression of most agr system target genes by 





βphenol soluble modulins (PSM), binding directly to their promoters in a RNAIII independent 
manner. Four different types of AIP are known to date and strains can be grouped according 
to the AIP produced. Each AIP type is able to activate agr system only in strains belonging to 
the same group (Fig.5). Conversely, AIP molecules can inhibit response of agr belonging to 
different groups. The agr system is further tuned by direct or indirect interconnection with 
several other transcription factors. The most relevant regulators of agr are SarA homologs. In 
fact, SarA induces RNAII transcription binding directly to the P2 promoter, while SarR 
downregulates transcription from P2.  
Figure 5. Schematic representation of the agr system. The system is encoded by two divergent 
transcripts, the RNAII that comprise agrBDCA genes and RNAIII transcript. agrD encodes for the 
propeptide, which is secreted and matured in AIP by AgrB. The AgrC senses the AIP, and activates 
AgrA. AgrA induces transcription from P2 and P3 promoters, and activates transcription of α and β 






3.4.2 Vancomycin resistance associated sensor-regulator  
The vancomycin resistance associated sensor-regulator (vraSR) TCS was firstly described as 
upregulated in Vancomycin Intermediate Staphylococcus aureus strains (VISA) [83]. VraS is 
the sensor HK that is composed by an N-terminal transmembrane domain and a C-terminal 
HK domain, while VraR is the response regulator of the system. The vraRS system is encoded 
downstream of a transcript containing other two genes of unclear function vraU and vraT 
(previously named yvqF). VraS responds to cell-wall affecting antimicrobials like 
glycopeptides, β-lactams, bacitracins by autophosphorylation and subsequent phosphorylation 
of VraR. VraR induces vra operon (vraUTRS) transcription and presumably controls the 
transcription of vra stimulon. It has been proposed that VraT is the actual sensor that interacts 
with VraS, influencing its autophosphorylation [84], while VraU role remains unknown to 
date. Mutations in this TCS can modulate (either increasing or diminishing) vancomycin 
resistance, as well as other antimicrobials. The broad spectrum of the stimulating agents 
suggests that the vraSR(T) senses cell wall damage and its activation determines the 















3.5 S. aureus vaccine development 
Considering the great burden of staphylococcal infections, and the remarkable ability to 
overcome antibiotic treatment by this pathogen, a vaccine against S. aureus would have an 
extremely beneficial impact on public health. Several attempts have been made for the 
development of a S. aureus vaccine, with different antigen composition [85-87], but only two 
have progressed to phase III clinical trials [88]. Merck’s V710, based on surface protein IsdB 
showed safety concerns in phase III trial [89], despite being protective in murine model and 
inducing of high antibody titers in rhesus macaque. NABI’s StaphVAX, composed by the 
capsular polysaccharide 5 and 8 coupled with a carrier protein, failed to meet the primary end 
point in two phase III clinical trials [90, 91].  
Several reasons behind this failure have been proposed [88, 92], but it is worth considering 
that so far both strategies are based on single antigen vaccines approaches. Given the 
redundancy and complexity of S. aureus pathogenesis, a multicomponent strategy may be 
more successful and other vaccines formulations in earlier stages of development include 
multivalent approaches. Despite the failures obtained so far, S. aureus vaccine research 
programs are still active [86-88].  
In recent years, SpA has been proposed as a promising vaccine candidate, showing efficacy in 
both passive and active immunization in animal models [64, 93-95]. A mutation within the 
IgG binding domains lead to the creation of a stable form of the protein void of ability to bind 
antibodies, named SpAKKAA [96]. Vaccination with this mutated protein in mouse elicited 
higher SpA specific antibodies and an increase of the IgG titers against other staphylococcal 
antigens after challenge with MRSA epidemic strain [96]. Moreover, vaccination with the 
SpAKKAA showed protection after challenge with different staphylococcal strains [96]. Passive 
immunization of mice with monoclonal antibodies was able to protect against MRSA and 
MSSA strains [93]. A later study demonstrated that immunization of mice with non-toxigenic 
SpA reduces nasal carriage rates in susceptible murine strains [97]. Similar results were 
obtained in guinea pig model, were the VH3 fraction in B cell population resemble human 







4 Aims of the study 
 
Given the central role of SpA in staphylococcal pathogenesis and the raising interest in SpA 
as potential vaccine antigen, we aimed at understanding the prevalence of SpA expression in 
staphylococcal isolates. To do so, we set out to screen a large collection of strains for the 
expression of this virulence factor. We identified a subset of strains carrying the gene but void 
of expression to detectable levels of SpA (SpA
-
 strains). We investigated if the absence of 
SpA could be associated with genetic polymorphisms common to the SpA
-
 subset of strains 
and whether other changes in the virulence factor expression profile are associated with the 
SpA
-
 phenotype. The hypotheses are: 1) the lack of a major staphylococcal immune evasion 
system such as SpA may be complemented with upregulation of another factor with a 
redundant function, and 2) a regulatory effect altering SpA expression may also drive other 
changes in the regulatory network of additional virulence factor gene expression. We verified 
these hypotheses by investigating the expression dynamics of a large number of virulence 
factors during in vitro growth curves using a high throughput qRT PCR approach.  
On identifying other genes that exhibit significant alteration in their transcription profiles we 





groups of test strains.  
To understand the regulatory circuitry that may be involved in the phenotypic observations, 
we mapped the regulatory networks that exert control on the identified genes with altered 
expression. 
The study of the expression interplays among the most significant immune evasion systems 
will give a deeper insight on staphylococcal pathogenesis and support to the design of new 






5.1 Identification of a small subset of strains not expressing SpA 
Our first aim was to evaluate the presence of the spA gene and its expression in our collection 
of S. aureus strains. The collection was composed of 133 strains with different origins and 
different typing systems. In particular 72 isolates were collected in Vanderbilt University 
Medical Center (US) between 2005 and 2015 and were characterized according to the Pulse 
Field Gel Electrophoration typing (PFGE typing)[98], while the remaining 61 strains, 
including well characterized lab strains such as Newman, were collected from different 
locations and typed by Multilocus Sequence Typing (MLST) (Fig.6).  
The Vanderbilt subset was composed of 10 different PFGE types: USA100 (33 isolates), 
USA300 (16 isolates) USA400 (14 isolates), USA700 (8 isolates), USA200 (4 isolates), 
USA400 (3 isolates), USA1100 (3 isolates), USA 500 (2 isolates), USA1000, USA800, USA 
900 (1 isolate each), plus 2 isolates with uncertain typing.  
The remaining collection included strains belonging to 15 different clonal complexes (CCs) 
and 28 unique genotypes (STs) (Fig.6). The largest portion of the subset typed by MLST was 
composed of CC30 (9 isolates, STs 30-34-36), CC8 (10isolates, STs 8-239-250-254) and CC5 
(12 isolates, STs 5-228), while the rest of the CCs were represented by less than 4 isolates.  
Figure 6. Lineages in the S. aureus collection. The collection is divided in two main subsets 
according to the typing method used. The strains from the Vanderbilt subset were characterized by 
PFG electrophoration, the other by MLST. The majority of the strains belongs to USA100/CC5 and 





The collection was tested by PCR for the presence of the spA gene, and by Western blot for 
the expression of the SpA protein. Although all the strains carried the spA locus (data not 
shown), nine of them resulted negative by Western blot analysis (Fig.7). The SpA negative 
(SpA
-
 ) strains included the Mu50 strain [12], four USA100 strains (MB01, MM1, MM2, 
S27), two CC5 isolates from Italy (ITSA18, ITSA19) and two laboratory strains belonging to 
CC25, Lowenstein [99] and Reynolds [100]. To further investigate the reasons of the loss of 
SpA expression in the above-mentioned isolates, an equal number of strains were chosen as 
representatives of the SpA
+
 group. In particular, N315 strain [101], four USA100 and four 
CC5 strains were selected. 
N315 and Mu50 are well characterized strains, isolated in Japan in 1982 and 1998 
respectively [12]. These two strains were previously sequenced and compared, showing 96% 
of sequence identity [101] and both belong to USA100 lineage [98, 102]. Given their well-





 group respectively. 
Figure 7. SpA expression in a representative panel of strains. Western blot analysis on the SpA
-
 
strains and the representative panel of SpA
+
 strains. Samples were taken from exponential phase of in 








5.2 Comparative genomic analysis shows deletion in spA 5’UTR affects 
SpA expression in a subset of SPA
-
 strains  
After the identification of the SpA
-
 phenotype, we investigated the possible reasons for the 
loss of SpA expression. In particular, we investigated if at the level of genome sequence we 
could identify the genetic basis for the SpA
-
 phenotype that could be shared by the different 
SpA
-





), including N315 and Mu50. Comparative genomics analysis was performed 




The analysis showed that all the strains shared high sequence identity if compared to N315 
(Fig.8A). As expected, Mu50 resulted with higher similarity to the N315 genome, while S27 
is the isolate that carried the highest number of mutations. Most of the identified mutations 
are harbored in all the USA isolates, supporting that they are not responsible for the 
phenotype.  
Similar results were obtained using Mu50 as reference (Fig.8B). This analysis revealed a 
higher number of gaps in the other genome sequences, indicating several regions that are 
present only in the Mu50 strain. Moreover, the distribution of these mutations is more 
heterogeneous, as some of them are not carried by all the strains. Anyway, also in this case 
the same mutations are harbored in strains coming from both groups. As already reported, 
N315 showed a deletion in the coding sequence of arlR/S, a two component system known to 
be also a repressor of spA [103]. It was not possible to identify a single mutation carried by all 
the SpA
-
 strains and not present in any of the SpA
+
. However, three of the SpA
-
 strains 
(MB01, MM1, MM2) showed a deletion of eight nucleotides, six nucleotides upstream the 







Figure 8. Comparative genomic analysis using N315 or Mu50 as reference. The figure shows the 
genetic identity between the USA100 strains and the reference strains N315 and Mu50. The SpA
+
 
strains are depicted in orange, while the SpA
-
 strains in blue. The color scale is different for each 
strain. White gaps show regions present in the reference strain but absent in the analyzed genomes. 
The inner circle represents the reference strains. (A) Genomic comparison using N315 as reference. 





The sequence corresponding to the deletion (CAGGGGGT) and its position make it likely to 
contain a Ribosome Binding Site (RBS) sequence for the spA gene. 
Further analysis on the spA locus showed additional differences among the isolates (Fig.9). 
The spA gene in the Mu50 and N315 strain carried a deletion of 174 nucleotides that causes 
the expression of a shorter SpA protein that lacks the last IgG binding domain, as already 
shown in the Western blot (Fig.7). Moreover, S27 isolate carries several SNPs across the 
sequence, including the promoter, as well as a shorter X variable region. Most of these 
mutations are silent, and none of these is responsible for an early stop codon.  
Figure 9. Alignment of spA locus in the USA100 subset of strains . (A) Alignment of the spA locus 
of the ten strains analyzed. The upper bar highlights the sequence identity of the spA locus. The yellow 
arrow shows the position of spA coding sequence, and its orientation. The black bars represent the 
sequence in each strain and gaps correspond to deletions. (B) Magnification of the region upstream the 
coding sequence of spA. The start codon is highlighted in greenand the mismatch present in the MB01 
sequence is highlighted in yellow. The dashed gaps underline the deletion present in the 5’UTR region 





In order to investigate whether the deletion found in three of the SpA
-
 strain could be 
responsible for their SpA
-
 phenotype, we generated two translational fusions of the spA 
promoter and the 5’UTR region to a mCherry reporter with or without the deletion (Fig.10). 
While expression of the reporter was detected when the N315 spA gene upstream sequence 
was fused to mCherry, fusion of the sequence containing the deletion resulted in no 
fluorescence signal. This suggests that the mutation containing the RBS region may be 
responsible for abolishing SpA expression in the three identified strains. This genomic 
analysis showed that the genetic reasons for SpA
-
 phenotype are probably different among the 
different strains, however for the MB01, MM1 and MM2 strains the loss of SpA expression is 
caused by a mutation in spA untranslated region. 
Figure 10. Effect of the 5’ UTR mutation on reporter production. The graph shows the fluorescence signal 
obtained from overnight growth of E.coli transformed with pOS1 plasmid containing either the wt spA promoter, 
or carrying the RBS mutation fused to mCherry reporter gene. The empty vector control shows the signal from 









5.3 Comparative transcript profiling of 84 virulence related genes in the 
subpanel of USA 100 strains  
Our genomic analysis showed that the genetic reasons for the SpA
-
 phenotype are probably 
different among the different strains. For this reason, the SpA
-
 strains were further 
investigated using a high-throughput qRT PCR approach to analyze the transcripts of 
virulence related genes. A panel of 84 TaqMan assays of selected virulence related genes, was 
used together with the HD Biomark microfluidics system were used to perform comparative 
transcription profiling. The panel of genes has been previously selected (Haag et al., 
manuscript in preparation) to cover diverse factors expressed in different stages of 
staphylococcal infection process, including adhesion, invasion and immune evasion. It is 
known that virulence genes exhibit in vitro growth phase regulation [78], therefore the 
transcriptional profiling was performed by measuring the transcript levels of the 84 virulence-
related genes at five representative time points (early, mid and late exponential phase, early 
and late stationary phase) of the in vitro growth curve. The Heatmap in Fig. 11 shows the 
transcription kinetics of the selected genes in all the strains tested. Several assays were not 
able to detect any target transcript in S27 isolate, probably because of the high rate of 
mismatch between the probes and the targets sequences. All the genes were then clustered 
according to their transcription profiles through the growth and among the isolates. The 
majority of the genes expression is increased with respect to early log phase (0,5 OD) 
indicated by the yellow predominance in the heatmap. There are four main clusters 
representing different transcript kinetic profile. Cluster 1 comprises the genes whose 
transcription decreases during the growth like clfB and fnbB that are known to be upregulated 
in exponential phase (Fig.12) [42]. Cluster 2 includes the genes which are upregulated in mid-
exponential phase and then downregulated in stationary phase. This second cluster contains 
the isdA isdB, isdC and isdG genes, which are involved in iron metabolism and are part of the 
iron-regulated surface determinant pathway (Isd). sirA, an iron-regulated lipoprotein involved 
in iron metabolism, is also included in this cluster [104]. The genes comprised in cluster 3 are 
highly upregulated as the growth progress (Fig12). As expected, this cluster includes genes 
involved in the quorum sensing system agr, such as agrA and hld. In particular, agrA encodes 
for the response regulator of the system, while hld coding sequence is located onto the 





Figure 11. Transcript levels variation during in vitro growth curve. Each column represents one assay, while 
each row corresponds to a sample. Values are normalized to the first growth point (early stationary phase, 
OD0,5). The genes transcribed at lower levels compared to the first growth point are depicted in blue, and in 
yellow genes that are up-regulated. The bars on the two sides of the heatmap represent the four major clusters: 





Figure 12. Kinetic profiles of the four major transcription clusters. Black lines represent the mean values of 
single genes and the error bars show the standard deviation among the isolates. The mean profile of the genes 







Several genes that are known to be targets of the agr system are grouped in this cluster, like 
the capsule genes capA and cap5H, the alpha haemolysin hla, the gamma haemolysin 
(component B-C) hlgB and hlgC [105]. 
The genes in cluster 4 are moderately up-regulated during the growth, with the exception of 
the N315 where they appear down-regulated (Fig.11, Fig.12). This is particularly evident 
comparing the mean kinetic profile of N315 with the other strain (Fig.12, cluster 4).  
The spA gene is not present in any of these major clusters, but it clusters together with sasD, 
their transcription increases in mid log phase and goes down during the stationary phase. 
However, their kinetic varies considerably among the isolates, although the transcription 
profile of these two genes is similar within the same strain. For example, both spA and sasD 
show flat curves in Mu50 and MB01 strains (Fig.11). 
Focusing on spA transcription, it is clear how the variability of spA transcript in SpA
-
 strains 
follows the upregulation of spA itself, which has the highest expression in the exponential 
phase. In Fig. 13 the spA transcription kinetic is shown in detail for each strain, considering 
the different relative steady state levels, and highlighting three different behaviors. Two of the 
strains with the RBS mutation (MM1, MM2) maintained the kinetic of expression of the SpA
+
 
strains, even though at lower steady state in comparison with SpA
+
 strains. Strains MB01 
(that harbor the RBS mutation) and S27 maintained only partially this profile as reflected by 
the flatter curve. MU50 shows a completely flat trend, with similar transcript levels across the 
growth. This means that some of the SpA
-
 strains lost spA regulation during growth other than 
expressing lower steady state spA transcript. 
The difference in transcription kinetics among the isolates was further investigated by 
clustering the data both by assays and by samples. Vertical colored bars in Fig.14 show that 
N315, Mu50 and S27 samples are grouped by strain, while the samples from the other isolates 
cluster according to the growth phases. This indicates that the overall differences within the 
growth phases of N315, Mu50 and S27 are lower than the one displayed with the other 
strains, whose similarity is higher within the same growth phase rather than within the same 
strain. In particular, mid and late exponential phases are well distinguished, while early and 
late stationary phases cluster together. This analysis showed that the profiles of N315, Mu50 





Figure 13. spA transcript profiles in all the SpA+ and SpA- strains. The black lines indicate the transcript 
profile of the SpA
+
 strains, while the coloured ones represent the spA RNA levels in the SpA
-
 strains. All the 
values are normalized to the mean of the SpA
+
 strains in the early exponential phase. The three strains that carry 
















Figure 14. Heatmap shows the clusterization of the transcription profiles both by assays and samples. 
Colored bars indicate the different clusters and the ten strains. Horizontal colored bars indicate assays clusters, as 





5.4 Capsule biosynthesis operon transcription is higher in SpA- strains 




 strains, we calculated the 




 strains. The 
genes were ranked based on their up-regulation in one or the other group and plotted in to a 
heatmap (Fig.15). At the two extremities of the heatmap are shown the genes that were 
diversely expressed in each point of the growth, i.e. genes that are always upregulated in 
either group. The center of the heatmap shows that some genes had time point specific 
differences.  




 strains. The heatmap 




 strains at each time point. 
The genes that are more transcribed in the SpA
+
 strains are depicted in yellow, while the ones that are more 
transcribed in the SpA
-





The significance of the difference in transcription for each gene was assessed through a two-
way ANOVA, as shown by the volcano plot in Fig.16.  This analysis highlighted five genes 
that show significant difference in transcript levels, i.e. genes with a fold change higher than 
two and p-value lower than 0.05 among the two groups of strains. As expected the spA gene 
exhibits the highest upregulation in the SpA
+
 strains, while other two genes, sdrC and sasD, 
were upregulated in SpA
+
 strains with lower significance. Interestingly, two genes were 
upregulated in the SpA
-
 strains, the capsule biosynthesis related genes capA and cap5H. These 
two genes belong to the capsule biosynthesis operon (Fig.17) and are the first gene of the 
operon (capA) and the first gene of the capsular polysaccharide type 5 specific region 
(cap5H). Of note, cap5H transcript was not detected in S27 isolate, indicating that it probably 
belongs to a different serotype. 
Figure 16. Volcano plot showing genes with significant difference in transcription. Genes are displayed 




 strain along the entire growth, and 
the p value measuring the statistical significance associated. On the right, with positive mean difference, the 
genes that are more transcribed in the SpA
+
 strains, on the left, with negative mean difference, the genes that are 
more transcribed in the SpA
-
 strains. 
Figure 17 Schematic representation of the capsule biosynthesis operon. The arrows represent the open 
reading frames. In blue are highlighted the two genes present in the transcriptional screening, capA and cap5H 
are highlighted in blue. The operon is composed by 16 genes, four of which are specific for the capsular 





The transcriptional changes of spA, capA and cap5H genes during the growth are shown in 
the boxplots in Fig.18, highlighting how the difference in RNA levels between the two groups 
of strains is not constant, but changes during the growth. 
Figure 18. Transcription trends for spA, capA and cap5H. The boxplots show the transcription of the three 




 strains; bars show the median and whiskers the maximum and minimum values. 
The values are normalized by the mean of the SpA
+
 strains at OD 0,5. The dotted line represents the SpA
+
 mean 





The analysis performed allowed the identification of genes whose transcription is different 
among the two groups of strains throughout the growth, however, less evident transcriptional 
differences could occur in single phase of the growth. To deeper understand the differences in 




 strains, we investigated whether some of the genes 
had a significant difference in transcription at single growth points. In this analysis, all the 
genes were evaluated in each growth point separately, and the results are reported in the 
volcano plot in Fig.19. The spA gene resulted different in all the growth points, while capA 
and cap5H showed a significant difference in three and two growth phases respectively (late 
log phase, early and late stationary phase). All the remaining genes detected by this analysis 
had significantly different RNA levels only in one time point of the growth. The genes that 
were transcribed with significant difference throughout the growth, i.e. spA, capA, cap5H and 
sdrC, showed a similar profile, with the highest upregulation in the early stationary phase 
(Fig.20). The common kinetics in differential regulation makes it reasonable to address this 
expression profile to the same factor or combination of factors. Despite sasD was identified as 
one of the genes with a significant difference throughout the growth, no singular growth point 
was highlighted by this analysis (in early stationary phase the mean difference was 5, the p-
value 0.0581). Interestingly, all the remaining genes were differentially transcribed in late 
stationary phase (Fig.19, Fig.20B). In particular, sarA that is a well-known regulator [105-
107], was detected among them. To summarize, the comparative analysis of transcription 
kinetic highlighted two different groups of genes with similar profiles. The genes that showed 





 strains only in this growth phase. Conversely, the genes that have a significant 
difference in RNA levels throughout the growth show the highest difference in transcription 












Figure 19. Volcano plot showing the genes with significant difference in specific growth phases. Each dot 
represents one gene in one growth point. The genes and the corresponding OD are ordered by significance: spA 
(OD 8; OD10; OD 4; OD 2; OD 0,5), capA (OD 8, OD4, OD 10), cap5H (OD8, OD10) sdrC (OD 8), aur, clfA, 























 mean RNA levels, dotted lines highlights the fold two difference. (A) Differential 
transcription kinetic of genes with significant difference throughout the growth. (B) Differential transcription 






5.5  Absence of SpA does not influence directly cap operon transcription 
The anti-correlation between the spA and capsule transcripts, and their common localization 
on the cell wall, suggested that the two factors could compete for the same localization on 
bacterial surface. It is possible that the two factors are linked to a feedback loop regulation, in 
which the presence of one of the two directly inhibits the expression of the other. To 
investigate this hypothesis, we measured the RNA levels of capsule biosynthetic genes in a 
ΔspA background. Figure 21 shows capA and cap5H RNA levels in strain Newman wt and 
ΔspA. The transcript levels are similar in the two strains, probably slightly lower in the spA 
mutant. This suggests that the expression of SpA does not influence the transcription of the 
capsule biosynthetic genes, so their expression is probably balanced by an upstream 
regulatory network. The increased transcription of the capsule biosynthetic genes and the 
down regulation of spA could be determined by the impairment of this regulation. 
 
Figure 21. capA and cap5H RNA levels in ΔspA background. The graphs show capA and cap5H RNA levels 
in five growth points of an in vitro growth curve. Newman wild type and ΔspA were used. The experiment was 















Since spA and capsule expression do not interfere directly on each other transcription, we 
focused on the dissection of the regulatory network upstream the differentially transcribed 
genes, to identify factors that could be responsible for the phenotype. The genes whose 
deletion affects the transcription of the genes selected for transcript analysis were extracted 
from the SATMD Staphylococcus aureus Transcriptome Meta-Database [108]. The relevant 





strains throughout the growth are shown in Fig.22. Three different types of genes can be 
identified in the regulatory network. Seven genes (Fig.22, group  marked 1) are known to 





indicating that they are unlikely involved in the SpA
-
 phenotype. Twenty genes were shown 
to influence the transcription of only one of the two groups of genes differently expressed, 
implying that one single gene of this group cannot be responsible for SpA
-
 phenotype. Ten of 
the regulators (Fig.22 group marked 2) are reported to have an opposite regulatory activity 
(induction or inhibition) on the genes identified as having distinct profiles in SpA+ and SpA- 
group of strains. This suggests that a shift in the regulatory output of one of these could result 
in the transcriptional difference observed in the SpA- strains. Interestingly, a relevant number 
of regulators whose activity is consistent with SpA
-
 phenotype is involved in cell envelope 
stress signal sensing, cell wall synthesis regulation and antimicrobial resistance (vraTSR, 

















network was extracted from SATMD Staphylococcus aureus Transcriptome Meta-Database (core free). The 
yellow circles represent genes upregulated in SpA
+ 
strains, the blue circles represents the genes upregulated in 
the SpA
-
 strains. The dimension of the circle indicates the significance of the upregulation. Green circles 
represent genes, or combination of genes, whose deletions influence the transcription of the five genes of 
interest. The three regulators present in the assays are depicted with the same graphic representation of the 
differential transcribed genes. Red arrows represent a positive regulation, blue arrows negative regulation. 
Dotted lines represent interaction not found in the database, but in the literature. 1) Genes that influence 
transcription of both groups of genes, but which is not consistent with transcript analysis. 2) Genes that exert a 





Knowing that sarA gene is differently transcribed during the late stationary phase, we verified 
whether its regulon fits with our transcript data. The network represented in Fig.23 shows the 





 strains. SarA represses all the genes that have significant 
upregulation in the SpA
+
 strains, and induces those showing a significant upregulation in the 
SpA
- 
strains, except for sarA itself. This is consistent with sarA upregulation in the SpA
-
 
strains. However, the majority of SarA targets (80%) do not show a significant difference in 




 strains (smaller circle in the network). This could be 
explained by the interference of others regulator that can impair SarA effect. Moreover, it is 
important to consider that the genes reported in the network are not necessarily direct targets 
of SarA, and overexpression of SarA alone could be not sufficient for their upregulation. 
Figure 23. SarA regulon. The genes present in the screening and regulated by SarA are depicted in the figure 
according the group of strain in which they are up regulated (yellow for the genes upregulated in the SpA
+
, blue 
for the genes upregulated in the SpA
- 
strains), and the p-value of the upregulation transcription at late stationary 
phase (dimension of the circle). Red arrows represent positive regulation, blue arrows negative regulation. 





5.7  Capsule gene transcription and capsule production is higher in SpA- 
isolates of geographically distinct origin 
Having identified significant transcriptional differences in the USA100 subset of strains, we 
expanded the subset to include the remaining SpA
-
 strains as well as a control SpA
+
 group, 
verified the upregulation of capA and cap5H transcripts by qRT-PCR and quantified the 
relative amount of capsule produced by all strains. The capA and cap5H transcripts levels 
were quantified at a single time point (early stationary phase) by RT-PCR. As already 
observed in the USA100 subset of strains, the RNA levels of both genes were significantly 
higher in the SpA
-
 strains (Fig.24). 




 strains. Bars indicate the medians, whiskers 
the maximum and minimum values. All values are relative to the mean of SpA
+
 strains levels. Statistical 









To quantify the amount of capsule produced by the SpA
-
 strains, we performed a capsule 
immunoblot from single growth point (late stationary phase) (Fig.25).The analysis showed 
high variability in the amount of capsule among the different strains, although the highest 
quantity of capsular polysaccharide was detected in the SpA
- 
isolates. Moreover, four of the 
SpA
+
 strains (N315, CI709, ITSA6, ITSA14) produced no detectable capsule at the time point 
tested, while all SpA
-
 strains expressed capsule at detectable levels.  




 strains. Bars indicate the medians, whiskers the 
maximum and minimum values. All values are relative to the mean of SpA
+
 strains levels. Statistical 













5.8  SpA- phenotype does not influence biofilm production 
Since the strains that do not express SpA produce a higher amount of capsule, we investigated 
whether the altered expression of these components could lead to altered biofilm formation. 
Previous studies showed that SpA has a role in biofilm formation in Staphylococcus aureus 
[114, 115]. Staphylococcal biofilms are usually encased in an extracellular matrix formed by 
Polysaccharide Intercellular Adhesin (PIA) or poly-N-acetylglucosamine (PNAG). 
Alternatively, biofilm formation can occur in a polysaccharide independent manner, in which 
SpA plays an essential role. This SpA-dependent biofilm was identified for the first time in an 
arlRS mutant, the two-component system that is naturally mutated in N315. It is reasonable to 
hypothesize that biofilm production in N315 strain could be SpA-dependent, as well as in 
other SpA
+
 strains. Conversely, it is possible that the overexpression of the capsule in SpA
-
 
could play a role in biofilm formation. We addressed these hypotheses by measuring the 
biofilm formation in the USA100 subset of strain, using a N315 ΔspA to verify if SpA does 
have a role in biofilm formation. As shown in Fig.26, SpA deletion in N315 does not 
influence biofilm formation, which is comparable to the wt. Moreover, the totality of the other 
isolates shows lower levels of biofilm formation, irrespective of the presence or absence of 
SpA. This demonstrates that SpA is not necessary for N315 biofilm formation, and that the 
increased capsule amount in SpA
-
 does not enhance it. 
Figure 26. Biofilm formation in USA 100 isolates subset. The graph shows the absorbance relative to crystal 
violet staining, after 24h of incubation in 96 wells plates. The average of three independent experiments is 











 strains produce different amounts of capsule, we explored 
whether the quantity of capsule on the surface of the SpA
-
 strains was enough to elicit the 





 reference strains respectively, and the phagocytosis assay was set up using 
capsule-specific rabbit antisera as described in materials and methods. Phagocytic uptake was 
visualized by confocal microscopy and quantified by Flow cytometry. Figure 27 shows a 
representative example of the interaction between Mu50 and neutrophils in different 
conditions. In the absence of complement and serum no bacteria were associated to 
neutrophils, and no phagocytosis was detected. The presence of both complement and specific 
serum resulted in the interaction of all the bacteria with the neutrophils, leading to an almost 
complete phagocytic uptake.  
 
Figure 27. Effect of capsule specific serum and complement on Mu50 phagocytosis. Fixed bacterial cells 
were incubated with differentiated HL60 cells in the presence or absence of a source of complement and capsule 
specific antiserum. After 30’ of phagocytosis the cells were fixed, and the samples stained with total anti 
Staphylococcus aureus antibodies. After cell permeabilization the samples were stained again, with Vancomycin 
BODYPIconjugate. Finally, DAPI stain was applied directly through the mounting medium. DAPI stain binds 
DNA and shows neutrophils nuclei and bacterial cells (with lower intensity). Total bacterial are shown by the 








The effect of different serum dilutions and the presence or absence of a complement source 
was tested on both Mu50 and N315 strains (Fig.28). The minimal level of uptake observed in 
absence of either complement or serum was used as baseline level for both strains. In the case 
of Mu50 strain, the addition of capsule-specific antibodies alone induced the internalization of 
the bacteria in a dose-dependent manner, while the phagocytic uptake of N315 strain 
remained similar in either presence or absence of serum. The presence of complement alone 
determined an increased uptake for both strains, but higher in Mu50: this is probably due to a 
reduced susceptibility to phagocytosis in the absence of complement of the encapsulated 
strain [116]. The addition of both specific serum and complement strongly increased the 
uptake of the Mu50 bacteria but not of those of the N315 strain. This inefficacy of capsule-
specific antibodies is not due to an antiphagocytic effect of SpA because similar results were 
obtained in the N315 ΔspA control (data not shown). With these experiments we confirmed 
that SpA
-
 strains express higher quantities of capsule, and that this capsule amount is enough 
to elicit phagocytosis in the presence of capsule-specific antibodies. 




 phagocytosis. The graph shows the 
fluorescence associated to neutrophils after phagocytosis of fluorescent bacteria, under different conditions. The 
phagocytosis were performed in absence of both serum and complement (-S -C), in absence of complement and 
in presence of different serum dilution ( S -C), in absence of serum and in presence of complement inactivated 
(IC), in absence of serum and in presence of complement (-S +C), or in presence of both complement and 






S. aureus is a major human pathogen, responsible for a wide range of diseases from both 
community and hospital acquired infections. The emergence of antibiotic resistant strains and 
the lack of alternative treatments to antimicrobials make it a recognized medical need. The 
vaccine approach has been considered promising, but no vaccine has yet been successfully 
developed to licensure. The reasons for this failure to date may be several and this should be 
taken into consideration in the perspective of the development of new therapies and 
interventions. S. aureus has evolved a plethora of immune evasion mechanisms, which impair 
host defenses and prevent bacterial clearance. Moreover, different strains can express 
different combinations of virulence factors, making it unlikely that strategies targeting single 
antigens result efficacious. Identifying a broadly expressed combination of antigens is 
therefore crucial for the development of new vaccine therapies. This study aims to address 
these concerns, investigating the expression of the recently proposed antigen SpA, and its 
interplays with other virulence determinants. SpA exerts several roles in staphylococcal 
infections. Its ability to bind IgGs through the Fc portion can prevent opsonophagocytosis by 
sequestering antibodies and by displaying them on the bacterial surface in an incorrect 
orientation [63, 64]. On the other hand, SpA can also bind the VH3 domain of B cell receptors 
acting as a superantigen and thus leading to an impairment of the B cell response [66, 67]. 
Despite the crucial role of SpA in staphylococcal pathogenesis, the screening of a large library 
of strains, allowed us to identify a subset of strains not expressing SpA (SpA
-
). These strains 
had heterogeneous origin and characteristics, and except for laboratory strains Reynolds and 
Lowenstein, all belong to the USA100/CC5 lineages which are associated to HA-MRSA 
infections. Genomic analysis of the SpA
-
 strains did not show mutations in spA or regulatory 
genes common to all SpA
-
 strains. However, in three of the analyzed strains we detected a 
mutation in the RBS of the spA gene that impairs the expression of SpA likely through 
affecting translational initiation of the protein. The fact that the two other SpA
-
 isolates carry 
an intact spA locus indicates that the genetic basis by which the protein is not expressed is 
diverse and may involve transcriptional regulation. SpA
-
 strains showed lower levels of spA 
transcript, indicating that the SpA
-
 phenotype is determined by changes in mRNA steady state 
regulation. Moreover, it seems that the regulatory layers by which the loss of SpA expression 





similar spA transcription kinetic of SpA
+
 strains but with lower steady state levels. Strains 
MB01, which carries the RBS mutation, and S27 exhibit a lower upregulation during growth, 
while spA transcription in Mu50 strain is largely void of spA transcription. This indicates that 
there are several independent factors that control both spA steady state level and its 
transcription kinetics, and that alterations in diverse regulators may contribute to the SpA
-
 
phenotypes observed in the strains analyzed in this study. Many isolates of Staphylococcus 
have been described with polymorphisms within global regulators of virulence, for instance 
agr system, causing altered gene expression networks and resulting in heterogeneity in the 
circulating sub-populations. 
Importantly the fact that the SpA
-
 phenotype has occurred repeatedly through diverse 
mechanisms in geographically distinct locations, suggests that the loss of SpA expression may 
represent the response to a selective pressure under specific conditions.  
Given the major role of SpA in staphylococcal pathogenesis, we hypothesized that the loss of 
its expression may be associated to other changes in the virulence factors profile of the SpA
-
 
strains. Through transcriptional profiling of a large number of virulence determinants, two 
other genes, sdrC and sasD, were identified as downregulated in the SpA
-
 strains. These two 
genes encode for cell wall anchored proteins, and thus belong to a similar regulatory network 




 strains resides in 
the upregulation of the capsule biosynthesis operon in SpA
-
 strains. It is important to notice 
that these differences are not the only transcriptional changes occurring in the SpA
-
 strains but 
represent a major relevant characteristic that is shared by all the SpA
-
 strains, suggesting that 
capsule upregulation is a common correlated adaptation. The analysis of the regulatory 
networks behind the expression of the genes identified in the transcriptional screening led to 
several observations. The regulators shared by spA, sdrC and sasD genes are known to affect 
the same regulatory activity on those three genes, confirming the fact that they are part of a 
similar regulatory network. Conversely, the analysis of the factors influencing spA and 
capsule transcription showed that several regulators determine opposite effects on those two 
virulence factors, indicating that multiple systems closely control inverse regulation to 
balance the expression of capsule and SpA. Alterations in any one of the factors involved in 
maintaining this tight balance would lead to the inverse shift that we observed between the 
SpA
-





the cellular surface and somewhat redundant nature of their functions, especially in relation to 
evading opsonophagocytosis. Risley et al. [117] showed how the presence of capsule on the 
bacterial surface masks another major surface protein Clumping factor A (ClfA), inhibiting its 
binding to fibrinogen probably through steric hindrance. Similarly to the effect on ClfA, it is 
possible that the capsule may interfere with SpA functions, and therefore the bacterium would 
express them in alternative way. Moreover, Nanra et al. [118] demonstrated that, in strains 
expressing both capsular polysaccharide and SpA, protein A does not elicit an anti-phagocytic 
effect towards anti-capsule specific antibodies. Nonetheless, expression kinetics in the in vitro 
growth curve shows a distinct temporal regulation, with spA transcribed mostly in exponential 
phase while the capsule biosynthetic genes were upregulated during stationary phase.  





 strains (spA, sdrC, sasD and capsule) are all bound to and major 
components of the cell wall and it is reasonable that their expression must be finely-tuned in 
the context of cell wall synthesis. Interestingly, through the regulatory network analyses the 
regulators identified as ‘fitting’ the regulatory effects observed, namely vraTSR, walR, stk1, 
stp1, rpoB, clpP are involved in cell wall biosynthesis and often involved in the acquisition of 
low levels of vancomycin resistance in Vancomycin Intermediate Staphylococcus Aureus 
(VISA) isolates [110]. VISA strains acquire resistance through several cumulative mutations 
allowing the bacteria to reduce vancomycin susceptibility [13]. Those mutations can be 
different among the VISA isolates and are mostly associated to key regulatory genes that 
determine an increased thickness of the cell wall [13, 17, 110, 119]. This process is not only 
cumulative, but also reversible, indicating that there is a fitness cost that renders it 
advantageous only in determined condition [13, 17, 119]. Other features associated to the 
VISA phenotype have been reported, and in particular lower SpA expression and the higher 
capsule production [83, 119-122]. The production of capsular polysaccharide itself was shown 
to not alter the Vancomycin resistance [122], suggesting that its overexpression is the 
consequence of the rearrangements of the regulatory network modulating its transcription. 
The similar transcription profile shown by the strains analyzed in the present study led us to 
hypothesize that the SpA
-
 strains in our collection could have enhanced Vancomycin 
resistance. By performing a vancomycin resistance test we verified that the SpA
-
 analyzed in 





although they share some phenotypic characteristic of the VISA isolates. Therefore, the 
overexpression of capsule in strains not expressing SpA is not a feature limited to the VISA 
phenotype. 
It is possible that SpA
-
 phenotype, that involves two major virulence and immune evasion 
factors, has a strong influence on host pathogen interaction. Indeed, several studies, based on 
both clinical or laboratory evidences, reported that VISA strains are associated to reduced 
virulence [123-126]. Moreover, it seems that VISA strains are associated to lower risk of 
shock and reduced systemic inflammatory response [123], suggesting that those strains are 
less likely to cause acute clinical manifestation but more likely to be persistent [127, 128]. It 
was proposed that the phenotypic features of VISA strains may be the consequences not only 
of antimicrobial treatment, but also of changes in host pathogen interactions [119, 120]. In 
other words, the features exhibited by VISA phenotype suggest that the host environment has 
an impact in the adaptation of these isolates, prompting a combined resistance and persistent 
phenotype. Another staphylococcal phenotype associated to persistence is the Small Colony 
Variant (SCV) phenotype [127]. The SCV strains are associated with significant growth 
defects and other phenotypic changes, that lead to an increased persistence in host cell [129]. 
A recent comparative transcriptomic study, among other transcriptional changes, showed a 
strong increase in capsule gene transcription and a lower spA RNA in SCV clones compared 
to parental strain [130]. The presence of this common expression pattern in diverse clinically 
relevant phenotypes of S. aureus drives the hypothesis that the balance of SpA and capsule is 
a crucial feature in staphylococcal infection that contributes to determine virulence and host-
pathogen interaction. Moreover, it is interesting to notice that despite the changes in 
expression of these two virulence factors, their genes are not affected by major mutations, 




 phenotype and vice 
versa to adapt to different conditions. It is worth noting that the SpA- strains that we identified 
from 2 geographically distinct sets of clinical isolates are within the USA100/CC5 lineage 
associated with HA-MRSA strains, suggesting that the adaptation to a SpA
-
 phenotype may 
occur preferentially in hospital acquired infections. 
In the context of vaccines research this peculiar balance is of major relevance when 
considering prophylactic strategies targeting one of these two major virulence factors, SpA or 





against all strains due to the identified population of SpA
-
 strains that are circulating and 
causing disease in geographically distinct locations. Here we show that a SpA
-
 strain is highly 
susceptible to the opsonic killing of anti-capsule antibodies, therefore suggesting that an 
intervention/vaccine strategy targeting both factors could be used for extending the coverage 
of a SpA–based vaccine to the broadest number of staphylococcal strains. 
On the other hand, a vaccine strategy using capsular polysaccharide as unique antigen was 
already developed but failed in phase III clinical trial [90, 91]. Interestingly, the Lowenstein 
and Reynolds strains which exhibit SpA
-
 phenotype were used for assaying capsular 
functional antibodies in both vaccine development and in clinical readouts from vaccine 




One of the reasons of the capsule-based vaccine failure could be the emergence of strains with 
no or low capsule, as we had shown that SpA
+
 strains may be not susceptible to capsule 
specific antibodies due to the absence of the antigen. In particular the USA300 lineage, which 
in the past years became the predominant epidemic CA-MRSA strain in US, was shown to 
lack the capsular polysaccharide due to conserved mutations in the capsule biosynthetic 
operon [24]. The presence of a wide spread number of strains that differs in virulence, and the 
development of several phenotypes through the adaptation to the host suggest that a 
multicomponent strategy is fundamental in staphylococcal vaccine design. Using the high 
throughput qRT PCR approach we compared the transcription of a large number of selected 
virulence determinants in a panel of strain, obtaining a highly detailed and time resolved 
expression profile. Its analysis allowed us to identify peculiar interplays in the expression of 
virulence determinants, which would have been impossible to detect by genomic screening. 
From this study, we identify that SpA and capsule could be combined in a vaccine approach 
to effectively target a broader range of strains with phenotypic adaptations involving 
virulence determinants. 
The implementation of this approach would provide a powerful tool for the evaluation of S. 
aureus virulence in a large number of strains and a useful support for the development of new 







7 Materials and methods 
7.1 Strains and growth conditions 
S. aureus strains used in this study are listed in table 1. Staphylococcal strains were grown on 
plates at 37°C in trypticase soy agar (TSA) supplemented with 5% (v/v) of sheep blood. 
Liquid cultures were performed in tryptic soy brot (TSB, Dilfco Laboratories) at 37°C 
250rpm, from a 0.05 optical density (OD600) overnight preinoculum. Growth curves for each 
of the analyzed strains were performed in order to identify the OD corresponding to the 
diverse growth phases. The OD identified were OD600=0.5 for early exponential phase, 
OD600=2 for medium exponential phase, OD600=4 for late exponential phase, OD600=8 for 
early stationary phase, OD600=10 for late stationary phase. 
E. coli DH5α clones were grown at 37°C on LB plate or LB broth, supplemented with 100µg 
ml
-1
 of ampicillin if necessary. 
7.2 Western blot analysis 
S. aureus isolates were grown in liquid to OD600 = 0.6. Samples were pelletted and 
resuspended in Lysis buffer (Tris HCl 50mM, MgCl2 20mM, Raffinose penta-hydrate 30%) 
supplemented with complete protease inhibitor cocktail (Roche), then treated with lysostaphin 
10’ at 37°C. The suspensions were centrifuged at 6000g for 20’and the supernatant retained. 
Protein concentration was quantified through BCA. Equal protein amounts were loaded onto a 
4-12% Bis-Tris precast gel (invitrogen) and then transferred onto a nitrocellulose membrane 
using iBlot Gel Transfer Device (ThermoFisher). For SpA detection the membrane was 
incubated with SpA-specific chicken antibodies, conjugated with biotin. The membrane was 
then incubated with HRP conjugated streptavidin and developed using Pierce ECL Western 
Blotting substrate (ThermoFisher). Alternatively SpA was detected as previously reported 
[48], probing the membrane with HRP-conjugated rabbit anti-mouse IgG (1:2,000 Dako). 
7.3 Genomic DNA extraction, sequencing and assembly 
Genomic DNA was extracted from overnight growth using GenElute Bacterial Genomic DNA 
Kit (Sigma-Aldrich) and manufacturer instructions adapted for S. aureus DNA extraction. 
Overnight growth of S.aureus were pelleted and re-suspended in TSM buffer (50mM Tris-





The suspensions were incubated until lysis, before the addition of 2µl of proteinase K 
(GenElute Bacterial Genomic DNA Kit). The extraction continued following the kit 
instructions. 
Sequencing was performed with HiSeq 2500 Sequencing System from Illumina and Paired-
Ends. 
Paired reads were assembled using CLC genomic work bench (Qiagen). 
BRIGG analysis was performed for all the genomes, using either Mu50 or N315 as reference.  
High resolution alignments of specific DNA regions were performed extracting the sequences 
using BLAST and then aligning them with MUSCLE algorithm in geneious software. 
 
7.4 spA promoter reporter system 
The promoter and the 5’UTR of spA gene were fused to mCherry in a pOS1 plasmid 
backbone [136]. The primers NWMN_0055_-266_EcoRI_F/ NWMN_0055_-1_R were used 
to amplify the spA promoter and 5’UTR region from Newman genomic DNA, while 
StamCh.R/StamCh.F primers were used to amplify the mCherry gene. The two amplicons 
were fused through fusion PCR thanks to the complementary sequences of StamCh.F and 
NWMN_0055_-1_R. The resulting fusion of spA promoter and 5’UTR-mCherry was cloned 
into the pOS1 vector using EcorI-PstI restriction sites generating the pOS1pspA. The 
pOS1pspA was modified to obtain the variant of the spA promoter lacking of the RBS by 
whole plasmid PCR. The primers RBS_KO_pspA_F and RBS_KO_pspA_R were designed to 
anneal on the region to be modified, but carrying the RBS mutation. The PCR product was 
digested by DpnI and transformed into E. coli DH5α competent cells and several clones were 
sequenced to identify plasmid containing the mutation, named pOS1pspARBS. DH5α clones 
carrying the empty pOS1 plasmid, the wt promoter 5’UTR-mCherry fusion and the variant 
containing the RBS mutation were grown overnight in LB + 100µg/ml ampicillin, and the 







7.5 RNA extraction and cDNA synthesis 
Samples for RNA extraction were collected from S. aureus isolates grown in liquid to the 
needed growth phase and stabilized using RNAprotect Bacteria Reagent (QUIAGEN, 
Germany) according to the manufacturer’s instructions. Bacterial pellets were then either 
directly processed or stored at-80°C. The bacterial pellet was resuspended in 1 ml of Trizol 
reagent (Ambion) and lysed in a FastPrep-24 homogenizer (MP Biomedicals) using three 
cycles of 60 s at 6.5 m s
-2
 followed by 5 min incubation on ice after each cycle. Chloroform 
was then added in 1:5 ratio, the suspension mixed and centrifuged for 15’. The resulting 
aqueous upper-phase was retrieved and the RNA was purified using the PureLink kit 
(Ambion) applying an on-column DNase digestion step using the RNase-free DNase kit 
(QIAgen) according to the manufacturer’s instructions. Residual DNA was removed by a 
second DNase treatment using RQ1 DNase (Promega) followed by a second RNA 
purification using the PureLink kit. RNA quality was assessed by gel electrophoresis and the 
absence of residual DNA was confirmed by qRT-PCR. cDNA synthesis was performed with 
SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen-Life Technologies) 
according to the manufacturer’s instructions, using random hexamer primer for reverse 
transcription (RT) on 300 to 2000 ng of total RNA. 
7.6 Virulence factor transcription profile 
The virulence factors transcription profile was assessed using the high-throughput qRT-PCR 
system BIOMARK HD (Fluidigm), with 83 TaqMan assays specific to virulence related 
genes (Table 3). To carry out the experiment in the BIOMARK system is necessary to 
perform a preamplification step in order to have samples with enough concentrated DNA 
template. Preamplification of the samples was performed with pooled primers relative to the 
genes to be tested in the assays. 2,5 ng of cDNA were amplified using the following cycling 
parameters: 95°C for 10 min; 10 cycles of 95°C for15s and 60°C for4 min. Each sample was 
diluted 1:5 using TE buffer and loaded onto a 48.48 Dynamic Array IFC (Fluidigm), 
following manufacturer instructions. Two Chips containing different sets of assays were used, 
both containing two technical replicates of the housekeeping gene gyrB. Two controls with 
TE and Tris diluted preamp mix respectively were included in each Chip. A Tris control was 
also included in the assays set. Raw data were manually checked for signals in the negative 





the mean of the gyrB replicates for each Chip. For the transcription kinetic profiles all the 
samples were normalized to the early stationary phase using the ΔΔct method. Clusterization 
of genes or samples was performed using the Multiple array viewer (Mev) application with 
Hierarchical Clustering, Pearson correlation as distance metric. 




 strains was performed using 





 strains was calculated for each gene at each time points; two-way ANOVA was used to 
establish the significance of the difference comparing values at same time points, and 
correcting for multiple comparisons by Sidak correction. 
7.7 qRT-PCR  
qRT-PCR was done using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen-Life 
Technologies) using ROX as internal control on a STRATAGEN Mx3000P QPCR system 
using the following cycling parameters: 95°C for 10 min; 45 cycles of 95°C for 30 s, 55°C for 
30 s and 72°C for 30 s; 95°C for 1 min, 55°C for 30 s and finally 95°C for 30 s. Final data 
were analysed with the Δct method, normalizing samples to the expression levels of gyrB. 
Statistical significance was determined by t-test using GraphPad Prism 7 software. 
7.8 Capsule immunoblot 
S. aureus isolates were grown to OD600=12, and then pelletted. The bacterial pellets were 
resuspended in 0.5% SDS, 5mM DTT, 100mM Tris and treated with proteinase K for 1h at 
45°C. Serial dilutions were loaded onto a nitrocellulose membrane, using a dot blot apparatus. 
The membrane was blocked with PBS-Milk 10%-Tween20 0.05% and then incubated with 
CP5-specific rabbit antiserum, followed by goat anti-rabbit HRP. The blots were developed 
using the Pierce ECL Western Blotting substrate (ThermoFisher), the image acquired using 
Chemidoc (BIORAD) and analysed with Imagelab (BIO RAD). Statistical significance was 







7.9 Knock out strain generation 
N315 and Newman ΔspA strains were created by allelic exchange using the pIMAY system 
[137]. This system was created to obtain clean gene deletions, and is based on the integration 
of the plasmid in the target DNA region and its following excision. The origin of replication 
of the pIMAY plasmid is highly temperature sensitive in staphylococci, as it allows the 
replication of the plasmid at temperatures below 30°C, while at 37°C plasmid integrants are 
selected. The excision of the plasmid at 28°C can generate two different alternative 
sequences: the wt sequence or a clean deletion of the target sequence. Anhydrotetracycline-
mediated induction of the secY antisense RNA prevents the growth of cells that retain the 
integrated plasmid and selects for the clones that lost the pIMAY [138]. For the generation of 
the spA mutant the upstream and downstream regions of the spA gene were amplified using 
two pairs of primers (spA_ko_DS_F/spA_ko_DS_R and spA_ko_US_R/spA_ko_US_F), 
fused together by fusion PCR and cloned into pIMAY vector using KpnI and SacI restriction 
sites. The plasmid was amplified in DC10B E.coli strain at 37°C and transformed into the 
intermediate S. aureus RN4220 at 28°C [137]. The plasmid was then amplified in the RN4220 
background at 28°C and transformed into N315 and Newman strain. The transformants were 
grown overnight in TSB + 10 µg ml
-1
 chloramphenicol at 28°C for plasmid amplification. The 
positive clones were inoculated in new pre-warmed TSB + 10 µg ml
-1
 chloramphenicol 
medium and grown overnight at 37°C to allow the integration of the plasmid. The cultures 
were plated onto TSA plates + 10 µg ml
-1
 chloramphenicol and grown overnight at 37°C. The 
resulting clones were inoculated in TSB medium without antibiotic, grown overnight at 28°C, 
and plated onto TSA plates + 1µg ml
-1
 anhydrotetracycline. The bigger colonies (the ones that 
did not show growth inhibition) were purified and tested for spa deletion by colony PCR 
using the spA-verif_F/ spA-verif_R pair of primers. The positive clones were then tested by 









7.10 Biofilm formation test 
The strains to be analyzed were inoculated in 200µl of TSB, with a 1:40 dilution from an 
overnight liquid growth in a 96 well plate. The plate was left at 37°C for 24h to allow biofilm 
formation. The plate was washed three times in water, and then dried. The samples were 
incubated 3’ in 100ul of crystal violet, and then the plate was rinsed 3 times in water, and 
dried. The dye was dissolved in 200ul of ethanol/acetone (80/20) and the absorbance was 
measured at 595nm using Tecan. Three independent replicates of the experiment were 
performed, with three technical replicates for each experiment. 
7.11 Phagocytic uptake experiment 
Phagocytic uptake was measured using a protocol similar to the one already described by 
Nordenfelt et al. [139].Overnight cultures were fixed in 1% paraformaldehyde and counted by 
flow cytometry (SOS1). Fixed bacteria were stained with FM-64fx (ThermoFisher) for 15’ in 
the dark, excess of fluorochrome was removed by washing in PBS.10^7 stained bacteria were 
incubated with rabbit anti capsule serum, 1% guinea pig complement and 10^6 HL60 
differentiated cells for 30’ in the dark. Cells were then washed in PBS and fixed in 1% 
paraformaldehyde for 20’. The samples were then washed and incubated in PBS 1%BSA and 
1:100 anti-Staphylococcus aureus polyclonal antibodies (ThermoFisher) for 1h 4°C in the 
dark. After a wash in PBS BSA, the samples were incubated in Rhodamine (TRITC) F(ab')2 
Fragment Goat Anti-Rabbit IgG (Jackson immunoresearch), for 30’ at 4°C. After a wash in 
PBS BSA and a second wash in PBS, the samples were re-suspended in PBS and read at 
FACS SOS1. Cells population was gated using forward scatter versus side scatter and then 
singlets were gated with SSCA vs SSC. Neutrophils with only internalized bacteria were 
gated selecting for FM64FX positive and TRITC negative events. For each sample, 10000 
events were analyzed using FlowJo software. In each sample, the delta geometric mean of the 
positive and negative populations was multiplied by the percentage of positive neutrophils, 













Newman Clinical strain, MSSA, CC8, ST254, CP5   Baba et al. J Bacteriol  2008
LAC Clinical strain, MRSA, USA300, SCCmec, IV, CC8, ST8, CP5 Miller et al. N Engl J Med  2005
MW2 Clinical strain, MRSA, USA400, SCCmec, IV, CC1, ST1, CP8 Baba et al. Lancet 2002
Mu50 Clinical strain, HA-VR-MRSA, USA100, SCCmec, II, CC5, ST5, CP5 Hiramatsu et al. J Antimicrob Chemother  1997
Staph19 Clinical strain, MRSA, SCCmec, IV, ST80, CP8  Bagnoli et al. PNAS 2015
NRS216 Clinical Strain, MSSA, ST30, CC30, CP8   Bagnoli et al. PNAS 2015
Reynolds Laboratory strain, MSSA, CC25, ST25, CP5   Karakawa et al. J Clin Microbiol  1985
Wright Laboratory strain, MSSA, CP8     Bagnoli et al. PNAS  2015
Becker Laboratory strain, MSSA, CP8     Cook et al. Hum Vaccin 2009
ATCC6538 Laboratory strain, MSSA, CC97, ST467, CP5   Bagnoli et al. PNAS  2015
Lowenstein Laboratory strain, MSSA, CC25, ST25, CP5   Fattom et al.  Infect Immun 1990
BD1686 Clinical strain, HA-MRSA, USA100, CC5, ST5, CP5  Bagnoli et al. PNAS  2015
BD1534 Clinical strain, HA-MRSA, USA200, CC30, ST36, CP8  Bagnoli et al. PNAS  2015
BD1449 Clinical strain, CA-MRSA, USA1000, CC59, ST59, CP8  Bagnoli et al. PNAS  2015
NRS382 Clinical strain, HA-MRSA, USA100, CC5, ST5, CP5  Bagnoli et al. PNAS  2015
NRS248 Clinical strain, MRSA, CC1, ST1, CP8   Bagnoli et al. PNAS  2015
NRS252 Clinical strain, MSSA, CC30, ST30, CP8   Bagnoli et al. PNAS  2015
Staph 15 Clinical strain, CA-MRSA, ST30, CC30, CP8   Bagnoli et al. PNAS  2015
Staph 17 Clinical strain, CA-MRSA, ST8, CC8, CP5   Bagnoli et al. PNAS  2015
Staph 18 Clinical strain, CA-MRSA, ST8, CC8, CP5   Bagnoli et al. PNAS  2015
Staph 21 Clinical strain, CA-MRSA, SCCmec, IV, ST80, CP8  Bagnoli et al. PNAS  2015
MSSA 94 ISS Clinical strain, MSSA, CC22, ST22, CP5   Bagnoli et al. PNAS  2015
IT-SA1 Clinical strain from infective endocarditis, CC30, ST30, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA2 Clinical strain from infective endocarditis, CP8   Rindi et al. Eur J Clin Invest  2006
IT-SA3 Clinical strain from infective endocarditis, CC101, ST101, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA4 Clinical strain from infective endocarditis, CC30, ST34, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA5 Clinical strain from infective endocarditis, CC8, ST8, CP5 Rindi et al. Eur J Clin Invest  2006
IT-SA6 Clinical strain from infective endocarditis, CC5, ST5, CP5 Rindi et al. Eur J Clin Invest  2006
IT-SA7 Clinical strain from infective endocarditis, CC20, ST20, CP5 Rindi et al. Eur J Clin Invest  2006
IT-SA8 Clinical strain from infective endocarditis, CC15, ST15, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA9 Clinical strain from infective endocarditis, CC121, ST120, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA10 Clinical strain from infective endocarditis, CC15, ST15, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA11 Clinical strain from infective endocarditis, CC5, ST5, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA12 Clinical strain from infective endocarditis, CC72, ST72, CP5 Rindi et al. Eur J Clin Invest  2006
IT-SA14 Clinical strain from infective endocarditis, CC5, ST5, CP5 Rindi et al. Eur J Clin Invest  2006
IT-SA15 Clinical strain from infective endocarditis, CC45, ST45, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA16 Clinical strain from infective endocarditis, CC72, ST72, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA17 Clinical strain from infective endocarditis, CC121, ST120, CP8 Rindi et al. Eur J Clin Invest  2006
IT-SA18 Clinical strain from infective endocarditis, CC5, ST5, CP5 Rindi et al. Eur J Clin Invest  2006
IT-SA19 Clinical strain from infective endocarditis, CC5, ST5, CP5 Rindi et al. Eur J Clin Invest  2006
SW-ST239-III Clinical strain, MRSA, SCCmec, III, CC8, ST239, CP8 Bagnoli et al. PNAS  2015
SW-ST80-IV-PVL Clinical strain, MRSA, SCCmec, IV, pvl+, ST80, CP8 Bagnoli et al. PNAS  2015









SW-ST30-PVL Clinical strain, MRSA, pvl+, CC30, ST30 CP8  Bagnoli et al. PNAS  2015
SW-ST398 Clinical strain, MRSA, CC398, ST398, CP5   Bagnoli et al. PNAS  2015
SW-ST228-I Clinical strain, MRSA, CC5, ST288, CP5   Bagnoli et al. PNAS  2015
SW-ST8-IV Clinical strain, MRSA, CC8, ST8, CP5   Bagnoli et al. PNAS  2015
SW-ST88 Clinical strain, MRSA, CC88, ST88, CP8   Bagnoli et al. PNAS  2015
SW-ST45 Clinical strain, MRSA, CC45, ST45, CP8   Bagnoli et al. PNAS  2015
SW-ST42 Clinical strain, MSSA, Singleton, ST42, CP8   Bagnoli et al. PNAS  2015
SW-ST152 Clinical strain, MRSA, CC152, ST152, CP5   Bagnoli et al. PNAS  2015
SW-ST59 Clinical strain, MRSA, CC59, ST59, CP8   Bagnoli et al. PNAS  2015
BW01 Clinical strain, HA, USA 100     this study
CF Serology 29 Clinical strain, HA, USA 100     this study
CF Serology 33 Clinical strain, HA, USA 100     this study
CI 1434 Clinical strain, HA, USA 100     this study
CI 1438 Clinical strain, HA, USA 100     this study
CI 1492 Clinical strain, HA, USA 100     this study
CI 334 Clinical strain, USA 100     this study
CI 394 Clinical strain, HA, USA 100     this study
CI 398 Clinical strain, HA, USA 100     this study
CI 482 Clinical strain, USA 100     this study
CI 683 Clinical strain, HA, USA 100     this study
CI 697 Clinical strain, USA 100     this study
CI 709 Clinical strain, HA, USA 100     this study
CI 755 Clinical strain, USA 100     this study
CI 846 Clinical strain, HA, USA 100     this study
CO01 Clinical strain, USA 100     this study
DH1 Clinical strain, HA, USA 100     this study
DL1 Clinical strain, HA, USA 100     this study
DL2 Clinical strain, HA, USA 100     this study
DLBAL-L Clinical strain, HA, USA 100     this study
DLBAL-R Clinical strain, HA, USA 100     this study
GM1 Clinical strain, HA, USA 100     this study
GM2 Clinical strain, HA, USA 100     this study
JMH1 Clinical strain, HA, USA 100     this study
M016 LIM Clinical strain, CA, USA 100     this study
MB01 Clinical strain, HA, USA 100     this study
MM1 Clinical strain, HA, USA 100     this study
MM2 Clinical strain, HA, USA 100     this study
RT1 Clinical strain, HA, USA 100     this study
SGBAL Clinical strain, HA, USA 100     this study
CF Serology 22 Clinical strain, CA, USA 300     this study
CF Serology 26 Clinical strain, CA, USA 300     this study
CR01 Clinical strain, HA , USA 300     this study





Table 1 (continued). Staphylococcal strain used in this study 
 
Strains from BW01 to CF Serology 34 were provided by Isaac Thomsen and C. Buddy Creech from 
Vanderbilt University School of Medicine. 
 
Strain Description Reference
KC1 Clinical strain, HA, USA 300     this study
LH01_Hem Clinical strain, HA, USA 300     this study
MB02_Hem Clinical strain, HA, USA 300     this study
MG Clinical strain, HA, USA 300     this study
MM01 Clinical strain, HA, USA 300     this study
RF01 Clinical strain, HA, USA 300     this study
TH1 Clinical strain, HA, USA 300     this study
M 299 LIM Clinical strain, CA, USA 700     this study
SG4NQ Clinical strain, CA, USA 700     this study
SG6NH Clinical strain, CA, USA 700     this study
SG6NM Clinical strain, CA, USA 700     this study
SG9NS Clinical strain, CA, USA 700     this study
WB9nm Clinical strain, CA, USA 700     this study
WB9NO Clinical strain, CA, USA 700     this study
WB9Nq Clinical strain, CA, USA 700     this study
WB4NT Clinical strain, CA, USA 1100     this study
TR10NK Clinical strain, CA, USA 1100     this study
TR10NL Clinical strain, CA, USA 1100     this study
Serology 2 Clinical strain, CA, USA 300     this study
Serology 12 Clinical strain, CA, USA 100     this study
Serology 16 Clinical strain, CA, USA 100     this study
Serology 21 Clinical strain, CA, USA 500     this study
Serology 22 Clinical strain, CA, USA 200     this study
Serology 23 Clinical strain, CA, USA 500     this study
Serology 27 Clinical strain, CA, USA 100     this study
Serology 28 Clinical strain, CA, USA 300     this study
Serology 36 Clinical strain, CA, USA 200     this study
CF Serology 1 Clinical strain, HA, USA 200     this study
CF Serology 2 Clinical strain, HA, USA 400/700     this study
CF Serology 5 Clinical strain, HA, USA 200     this study
CF Serology 10 Clinical strain, HA, USA 300     this study
CF Serology 11 Clinical strain, HA, USA 400     this study
CF Serology 16 Clinical strain, HA, USA 900     this study
CF Serology 25 Clinical strain, HA, USA 1000     this study
CF Serology 30 Clinical strain, HA, USA 400     this study
CF Serology 31 Clinical strain, HA, USA 300/200     this study
CF Serology 32 Clinical strain, HA, USA 800     this study
CF Serology 34 Clinical strain, HA, USA 400     this study
RN4220 Laboratory strain, restriction-deficient mutant Kreiswirth et al. Nature 1983











Ori+ for Gram-positive strains; Ori− (pBR322) 






pOS1 derivative harboring spA promoter and 





pOS1pspA derivative carriyng the 5'UTR variant 





plasmid vector for allelic replacement; 
Temperature-sensitive Gram-positive replicon, 
tetracyclin inducible secY antisense 
chloramphenicol 
Monk et al. MBio, 
2012 






















Table 2. Oligonucleotides used in this study. Low case letters shows restriction sites, underlined 





StamCh.F ATGGTGTCAAAAGGTGAAGAAGATAATATG N/A 
amplification for 
fusion to Staph 
promoters 
this study 
StamCh.R GCTTGGctgcagTTATTTGTATAATTC PstI 
amplification for 



























spA_ko_DS_notI_F TATATAgcggccgcATTTAATTGGTGCAACTGGGAC NotI spA KO this study 
spA_ko_US_notI_R ATATATgcggccgcTTGCAGATCAAAGTGAATCACAG  NotI spA KO this study 








capA_rt_F TATCAACATCCAAGTTAAAAGTGG N/A qRT PCR capA this study 
capA_rt_R TCCAATATAACTGTATTCACCAATG N/A qRT PCR capA this study 
cap5H_rt GAAAAACCAGTCCTCTAAAGAATC N/A qRT PCR cap5H this study 








Table 3. TaqMan assays used in this study 
 























































esaB NWMN_0221 esaB, TVIISS
essA NWMN_0221 essA, TVIISS
ebpS NWMN_1389 elastin binding protein
esaA NWMN_0220 essA, TVIISS
coa NWMN_0166 staphylocoagulase
eap NWMN_1872 MHC class II analog protein
clfA NWMN_0756
clumping factor A, fibrinogen-binding
protein A
clfB NWMN_2529 clumping factor B
capA2 NWMN_2563
capsular polysaccharide biosynthesis 
protein capA2
chp NWMN_1877 chemotaxis-inhibiting protein CHIPS
cap5H NWMN_0102 capsular polysaccharide 5
capA NWMN_0095 capsular polysaccharide synthesis enzyme CapA
atl NWMN_0922 autolysin
aur NWMN_2536 zinc metalloproteinase aureolysin
ahpC NWMN_0372 Alkyl hydroperoxide reductase subunit C
asp23 NWMN_2086 alkaline shock protein 23
adsA NWMN_0022 adenosine synthase A





Table 3 (continued). TaqMan assays used in this study 
 























































hlgB2 NWMN_2320 gamma hemolysin, component B
hlgC NWMN_2319 gamma-hemolysin component C
hld NWMN_2624 delta-hemolysin, RNAIII
hlgA NWMN_2318 gamma-hemolysin component A
hla NWMN_1073 alpha-hemolysin precursor
hlb NWMN_1926 beta-hemolysin
geh NWMN_0262 triacylglycerol lipase
gyrB NWMN_0004 DNA gyrase subunit B
fnbA NWMN_2399 fnbA, C-term truncation in Newman
fnbB NWMN_2397 fnbB, C-term truncation in Newman
fhuD2 NWMN_2185
hydroxamate siderophore binding 
lipoprotein 
FLIPr NWMN_1067 FLIPr
eta NWMN_1082 exfoliative toxin A
fbp NWMN_1119 fibronectin/fibrinogen-binding protein
esxA NWMN_0219 esxA secreted protein
esxB NWMN_0225 esxB secreted protein
essB NWMN_0222 essB, TVIISS





Table 3 (continued). TaqMan assays used in this study 
 























































mntA NWMN_0603 ABC transporter ATP-binding protein  
mntH NWMN_0971
Mn2+/Fe2+ transporter NRAMP 
family protein
lukS NWMN_1928 leukocidin LukS subunit
mgrA NWMN_0655 MgrA - MarR family regulatory protein
lukD NWMN_1718 leukocidin LukD subunit
lukE NWMN_1719 leukocidin LukE subunit
ltaA NWMN_0886 glycolipid permease LtaA
ltaS NWMN_0687
glycerol phosphate lipoteichoic acid 
synthase
isdG NWMN_1047 cytoplasmic heme-iron binding protein
isdH NWMN_1624
haptoglobin-binding surface anchored 
protein
isdB NWMN_1040 iron-regulated heme-iron binding  protein
isdC NWMN_1042 iron-regulated cell surface protein
isaB NWMN_2537 immunodominant antigen B
isdA NWMN_1041 iron-regulated heme-iron binding  protein 
icaB NWMN_2567 intercellular adhesion protein IcaB
isaA NWMN_2469 immunodominant antigen A
hlgC2 NWMN_2319 gamma-hemolysin component C





Table 3 (continued). TaqMan assays used in this study 
 























































sbi NWMN_2317 immunoglobulin G-binding protein Sbi
scn NWMN_1876
staphylococcal complement inhibitor 
SCIN 
sasF NWMN_2545 similar to functionally unknown protein
sasG NWMN_2392 cell wall surface anchor family protein 
sasC NWMN_1649 similar to fmtB protein, cell wall anchored
sasD NWMN_0078 similar to functionally unknown protein
sasA NWMN_2553 serine-threoinine rich antigen
sasB NWMN_2061
methicillin resistance determinant 
FmtB protein
sarS NWMN_0056 SarS transcriptional regulator
sarZ NWMN_2286 SarZ - MarR family regulatory protein
sarA NWMN_0588 SarA transcriptional regulator
sarR NWMN_2195 SarR transcriptional regulator
saeP NWMN_0677 SaeRS auxiliary protein
sak NWMN_1880 staphylokinase 
NWMN_0851 NWMN_0851 putative surface protein
NWMN_1231 NWMN_1231
ABC transporter (ATP-binding protein) 
homolog
nuc NWMN_1236 thermonuclease



















































secreted von Willebrand factor-binding 
protein
sta011-06 NWMN_0403 staphylococcal tandem lipoprotein
sta011-16 NWMN_2379 staphylococcal tandem lipoprotein
sta011-01 NWMN_0042 staphylococcal tandem lipoprotein
sta011-05 NWMN_0148 staphylococcal tandem lipoprotein
sspA NWMN_0918
V8 protease, glutamyl endopeptidase 
precursor
sspB NWMN_0917 cysteine protease, staphylopain
sirA NWMN_0059
siderophore compound ABC transporter 
binding protein
spa NWMN_0055 Immunoglobulin G binding protein A
scpA NWMN_1403 Staphopain A, cystein protease
sdrC NWMN_0523
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